ArticleBMC cancer2025
Fusions4U: a resource of validated and annotated gene fusions in 328 cancer cell lines.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLarge-scale genomic rearrangements in cancer cells can lead to the creation of fusion genes which alter the expression or function of the partner genes. Some fusion genes act as tumour drivers and the use of kinase inhibitors in patients with specific fusions have led to breakthroughs in cancer therapy. The large clinical and scientific interest in fusions has led to the development of software that use RNA sequencing data to identify fusion transcripts. Unfortunately, fusion transcript callers output many predictions which lack underlying genomic rearrangements and large datasets with validated fusions are scarce.
resultsThis paper and the accompanying Fusions4U web application present a resource of validated and annotated gene fusions for 328 cell lines from the Cancer Cell Line Encyclopedia. Predicted fusion transcripts from Arriba and STAR-Fusion were analysed with our published validation pipeline that uses matched whole-genome sequencing data to identify discordantly mapped read pairs and candidate genomic breakpoints that support genuine fusion events. This resulted in 8,753 and 2,244 validated fusion transcripts for Arriba and STAR-Fusion predictions, respectively, with 1,596 fusions common to both. Additional layers of annotation include alternative splicing of fusion transcripts, kinases, microRNA host genes, genes in the COSMIC Cancer Gene Census, as well as known fusion gene pairs from the Mitelman Database of Chromosome Aberrations and Gene Fusions in Cancer and the TumorFusions dataset. We furthermore analysed information about fusion genes together with cell line data from the PRISM drug repurposing screening as an example of how this dataset can be used.
conclusionsThis resource can be used to design experiments for functional studies and drug development, alone or in combination with publicly available information for the Cancer Cell Line Encyclopedia cell lines. The large collection of validated fusion transcripts with candidate genomic breakpoints can also be used in development and evaluation of bioinformatic tools for fusion transcript detection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.